An interventional study of Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100 in Depression, sponsored by Institute of Mental Health, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by Institute of Mental Health, Singapore · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Depression with a site in Singapore — 14 open to participants now, 18 under way, none of them phase 3. Depression · Singapore.
Among the 34 studies in Depression with a site in Singapore, this one is the 25th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 with no phase, reaches primary completion later than 2 of the 17 other live ones, and was the 19th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →14 of the 34 studies in Depression with a site in Singapore are open now. Recruiting first, the newest first:
Institute for Human Development and Potential (IHDP), Singapore · Sites in Singapore
Ages 21–75 · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 21+
KK Women's and Children's Hospital · Sites in Singapore
Ages 21–90
National University of Singapore · Sites in Singapore
Ages 21–64
Nanyang Technological University · Sites in Singapore
Ages 18–25 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 122 across the 25 interventional studies, 600 across the 9 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 34 have an industry lead sponsor. The 10 most frequent:
Institute of Mental Health, Singapore is the lead sponsor of 18 studies on the registry; 9 are open to participants now.
Institute of Mental Health, Singapore has 9 studies filed under Depression — fewer than ten, so there is no comparison to draw.
1 of the studies in Depression with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03408717KK Women's and Children's HospitalEvaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Depression with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This proposal seeks to conduct a pragmatic single arm, open label pilot implementation to validate our individualized functional Magnetic Resonance Imaging (fMRI) connectome-guided localization approach for accelerated TMS among Asian patients with depression.
Participants will be patients with Major Depressive Disorder not responding to standard treatment, with no exclusions to fMRI or transcranial magnetic stimulation (TMS) (essentially metal implants in the head) and willing to participate in the pilot.
All participants will undergo MRI scans before and after the accelerated TMS treatment. The multi-session hierarchical Bayesian model (MS-HBM) approach will be used to estimate individualized connectome-guided target locations.
Patients will undergo accelerated TMS applied to individualized connectome-guided target locations (based on the MS-HBM approach).
Patients will undergo 10 sessions (each session lasting 10 min) spread out over 10 hours each day for 5 consecutive working days.
All clinical outcome data will be collected for each patient by a pre-defined questionnaire at four time points: at baseline, post-treatment, 1 month and 3 months during follow-up.
The clinical outcome data will be analyzed using linear regression or repeated analysis of variance (ANOVA) after adjusting for baseline clinical characteristics and socio-demographics. Trajectories of the clinical outcome data at baseline, post-treatment and all follow-up time points will be plotted and compared with time series statistical analysis models with the other clinical and socio-demographic characteristics included as confounders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an accelerated intermittent theta burst stimulation (iTBS) treatment delivered with a MagVenture MagPro X100 system (MagVenture A/S, Denmark) equipped with a butterfly shaped MagVenture Cool-B65 A/P coil. The treatment course is comprised of 10 treatment sessions daily for 5 consecutive workdays for a total of 50 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 90%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions). All iTBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
Device: Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100
MagproX 100 and Axilium Cobot with Localite camera
Montgomery-Åsberg Depression Rating Scale (MADRS)
Clinician rated Depression rating scale, range of scores 0 to 60 with higher scores meaning a worse outcome
Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention
Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report) (QIDS-16)
Patient rated Depression rating scale, scored 0-27 with higher scores meaning a worse outcome
Time frame: Baseline, (Days 1-5 of treatment), immediately after intervention, 1 month and 3 months post intervention
Montreal Cognitive Assessment (MoCA),
global cognitive functioning, scored 0 to 30 with higher scores meaning better outcome
Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention
EuroQol- 5 Dimension (EQ-5D)
Quality of life scales, Visual analogue scale 0-100 with higher scores meaning better outcome
Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention
Quality of Life Enjoyment and Satisfaction Questionnaire Short form (Q-LES-QS-SF)
Quality of life scales, scored 0-70 with higher scores meaning better outcome
Time frame: Baseline, immediately post treatment, 1 month and 3 months post intervention
Correlation of changes in functional connectivity with changes in MADRS scores
Time frame: Baseline, immediately post treatment
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Apr 2025, 13 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Mental Health, Singapore